Clinical trials: Cancer (Advanced Stage)
Advanced Cancer
Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers
TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPα (Signal Regulatory Protein Alpha) and enhances the phagocytosis of cancer cells by macrophages.
- Trial name
- NCT05192512
- Testing
- TQB2928 injection
- Where
- 2 sites in China
- Volunteers
- 180 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Advanced Malignant Solid Tumors
HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors
A Phase I Study of HEC-921 Injection as Monotherapy and in Combination with Other AntineoplasticTherapy in Patients with Advanced Malignant Solid Tumors
- Trial name
- NCT07824934
- Testing
- HEC-921, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Soft Tissue Sarcoma
Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Advanced Soft Tissue Sarcoma.
- Trial name
- NCT00742963
- Testing
- TH-302
- Where
- 9 sites in United States
- Volunteers
- 107 people
- Sponsor
- ImmunoGenesis
Solid Malignancies, With or Without Lung Metastases
Improving Function,Welfare of Late-stage Cancer Subjects by ACC
To improve the function and welfare of late stage solid cancer subjects by: enabling subjects to benefit from a potentially promising drug under development assessing initial evidence of improvement in Pain VAS score assessing…
- Trial name
- NCT03057314
- Testing
- Amorphous Calcium Carbonate
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Amorphical Ltd.
Ovarian Neoplasms
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer.
- Trial name
- NCT02655016
- Testing
- Niraparib
- Where
- 116 sites in United States, Belgium and 12 more
- Volunteers
- 733 people
- Sponsor
- Tesaro, Inc.
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) as a monotherapy or in combination with immune checkpoint inhibitors in Subjects with…
- Trial name
- NCT07487519
- Testing
- HLX43 DOSE 1 IN ≥2L TNBC, HLX43 DOSE 2 IN ≥2L TNBC, HLX43 DOSE 1 + HLX10
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Non-Small Cell Lung Cancer
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs".
- Trial name
- NCT05785767
- Testing
- fianlimab, cemiplimab
- Where
- 106 sites in United States, Australia and 9 more
- Volunteers
- 149 people
- Sponsor
- Regeneron Pharmaceuticals
Non Small Cell Lung Cancer (NSCLC)
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase II clinical study designed to evaluate the safety and efficacy of JSKN033 in the treatment of patients with advanced NSCLC.
- Trial name
- NCT07283198
- Testing
- JSKN033 Injection
- Volunteers
- 160 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced KRAS G12D Mutant Solid Tumors
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
The study is being conducted to evaluate the safety and tolerability of HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation.To estimate the maximum tolerated dose (MTD) and/or a biologically active dose…
- Trial name
- NCT05533463
- Testing
- HRS-4642
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Lung Cancer, Non-Small Cell
A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors
This is an open-label, two-arm, Phase I, dose escalation study to evaluate the safety and tolerability and to determine the optimal tolerated regimen(OTR) of pazopanib in combination with gemcitabine (Arm A) or pazopanib…
- Trial name
- NCT00678977
- Testing
- Pazopanib (GW786034), Gemcitabine, Cisplatin
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Pancreatic Neoplasms
GEMOX: Oxaliplatin in Pancreatic Cancer
Primary objective: To evaluate overall response rate (based on RECIST criterion) Secondary objective: To evaluate time to progression, clinical benefit, quality of life and safety
- Trial name
- NCT00261092
- Testing
- Oxaliplatin
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Sanofi
Cancer
A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED)
The purpose of this trial is to study MK0731 in patients with recurrent or non-responsive solid tumors, or cancers for which standard therapy does not exist.
- Trial name
- NCT00104364
- Testing
- MK0731
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
This is a phase I, open-label study of D-0502 single agent and D-0502 in combination with standard dose of palbociclib to assess the safety and tolerability, identify an MTD, and/or RP2D, evaluate the PK properties and evaluate…
- Trial name
- NCT03471663
- Testing
- D-0502, palbociclib
- Where
- 15 sites in United States, China
- Volunteers
- 200 people
- Sponsor
- InventisBio Co., Ltd
Advanced or Metastatic Solid Tumors
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of HM16390, as a single agent and in combination with pembrolizumab to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced…
- Trial name
- NCT06724016
- Testing
- HM16390, pembrolizumab
- Where
- 7 sites in United States, South Korea
- Volunteers
- 292 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Locally Advanced Squamous Non-Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Cancer
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
The main purpose of this study is to evaluate the effectiveness and safety of gemcitabine-carboplatin plus necitumumab in chemotherapy-naïve participants with locally advanced or metastatic squamous non-small cell lung cancer.
- Trial name
- NCT02941601
- Testing
- Necitumumab, Gemcitabine, Carboplatin
- Where
- 19 sites in United States, Belgium and 5 more
- Sponsor
- Eli Lilly and Company
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
The purpose of this study is to treat patients with locally advanced or metastatic NSCLC with a combination therapy of selumetinib and two different doses of docetaxel 75mg/m2 or 60 mg/m2 vs placebo and compare how well each dose…
- Trial name
- SELECT-2 (NCT01750281)
- Testing
- Selumetinib 75 mg, Docetaxel 75 mg/m2, Docetaxel 60 mg/m2
- Where
- 68 sites in United States, Brazil and 6 more
- Volunteers
- 212 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.
The purposes of this study are to determine: 1. The safety of pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs. 2.
- Trial name
- NCT00061464
- Testing
- pemetrexed, gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Adult
New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer
A2A-004 is a three-part multicenter, open-label, Phase I clinical trial intended to evaluate the safety and tolerability, and the pharmacokinetics (PK) and food effect of new formulations of inupadenant (formerly known as…
- Trial name
- NCT05117177
- Testing
- Inupadenant
- Where
- 5 sites in Belgium, United Kingdom
- Volunteers
- 57 people
- Sponsor
- iTeos Therapeutics
Solid Neoplasms, Colorectal Neoplasms
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
This study will be conducted to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.
- Conditions
- Solid Neoplasms, Colorectal Neoplasms, Gastrointestinal Tumors
- Trial name
- NCT03833700
- Testing
- E7386
- Where
- 8 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Eisai Co., Ltd.
Solid Tumors
Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors
This is a first-in-human, multicenter, open-label study consisting of 2 phases. Phase 1 is a dose escalation study of RXDX-105 (formerly known as CEP-32496) in patients with advanced solid tumors aimed at defining the recommended…
- Trial name
- NCT01877811
- Testing
- RXDX-105
- Where
- 14 sites in United States
- Volunteers
- 143 people
- Sponsor
- Hoffmann-La Roche